文献速递胸部肿瘤

卡铂联合依托泊苷对比拓扑替康二线治疗敏感复发小细胞肺癌:开放标签多中心随机III期试验

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2020-01-01

这项在法国38家医院开展的开放标签随机III期试验纳入164例一线铂类联合依托泊苷治疗有效且≥90天后复发/进展的敏感复发小细胞肺癌患者,比较卡铂联合依托泊苷与口服拓扑替康的疗效。

要点

  • 两组3-4级不良事件以血液学毒性为主,联合组中性粒细胞减少和发热性中性粒细胞减少发生率低于拓扑替康组。
  • 拓扑替康组发生2例治疗相关死亡(发热性中性粒细胞减少伴脓毒症),联合组无治疗相关死亡。

核心结论

  • 卡铂联合依托泊苷再挑战可作为敏感复发小细胞肺癌合理的二线化疗选择。

研究设计与样本

  • 开放标签、多中心、随机III期试验,在法国38家医院开展。
  • 纳入164例组织学或细胞学确诊的IV期或局部复发小细胞肺癌患者,一线铂类联合依托泊苷治疗有效且末次治疗后≥90天复发/进展,ECOG PS 0-2,年龄≥18岁。
  • 按1:1随机分配至卡铂联合依托泊苷组或口服拓扑替康组,随机化采用最小化法并按ECOG PS、一线化疗反应和中心进行偏币平衡。
  • 主要终点为无进展生存期,中心审查并在意向治疗人群中分析。

主要发现

  • 最常见3-4级不良事件:中性粒细胞减少拓扑替康组18例(22%)vs联合组11例(14%);血小板减少29例(36%)vs 25例(31%);贫血17例(21%)vs 20例(25%);发热性中性粒细胞减少9例(11%)vs 5例(6%);乏力8例(10%)vs 7例(9%)。
  • 拓扑替康组发生2例治疗相关死亡(均为发热性中性粒细胞减少伴脓毒症),联合组无治疗相关死亡。

关键数值与推荐

  • 联合组方案:卡铂AUC 5 mg/mL/min静脉第1天,依托泊苷100 mg/m2静脉第1-3天,每周期21天,共6周期。
  • 敏感复发定义:一线铂类联合依托泊苷治疗有效且末次治疗后≥90天复发/进展。

临床怎么用

  • 对于一线铂类联合依托泊苷治疗有效且≥90天复发的敏感复发小细胞肺癌患者,可考虑卡铂联合依托泊苷再挑战作为二线化疗方案。
  • 治疗期间需监测血液学毒性,尤其是中性粒细胞减少和发热性中性粒细胞减少。

局限性

  • 开放标签设计,可能影响主观终点评估。
  • 样本量较小(意向治疗人群162例),研究仅在法国进行。
  • 随访时间有限,未报告总生存期数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small-cell lung cancer. This study investigated whether the doublet of carboplatin plus etoposide was superior to topotecan as a second-line treatment in patients with sensitive relapsed small-cell lung cancer. METHODS: In this open-label, randomised, phase 3 trial done in 38 hospitals in France, we enrolled patients with histologically or cytologically confirmed advanced stage IV or locally relapsed small-cell lung cancer, who responded to first-line platinum plus etoposide treatment, but who had disease relapse or progression at least 90 days after completion of first-line treatment. Eligible patients were aged 18 years or older and had an Eastern Cooperative Oncology Group performance status 0-2. Enrolled patients were randomly assigned (1:1) to receive combination carboplatin plus etoposide (six cycles of intravenous carboplatin [area under the curve 5 mg/mL per min] on day 1 plus intravenous etoposide [100 mg/m2 from day 1 to day 3]) or oral topotecan (2·3 mg/m2 from day 1 to day 5, for six cycles). Randomisation was done using the minimisation method with biased-coin balancing for ECOG performance status, response to the first-line chemotherapy, and treatment centre. The primary endpoint was progression-free survival, which was centrally reviewed and analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02738346. FINDINGS: Between July 18, 2013, and July 2, 2018, we enrolled and randomly assigned 164 patients (82 in each study group). One patient from each group withdrew consent, therefore 162 patients (81 in each group) were included in the intention-to-treat population. With a median follow-up of 22·7 months (IQR 20·0-37·3), median progression-free survival was significantly longer in the combination chemotherapy group than in the topotecan group (4·7 months, 90% CI 3·9-5·5 vs 2·7 months, 2·3-3·2; stratified hazard ratio 0·57, 90% CI 0·41-0·73; p=0·0041). The most frequent grade 3-4 adverse events were neutropenia (18 [22%] of 81 patients in the topotecan group vs 11 [14%] of 81 patients in the combination chemotherapy group), thrombocytopenia (29 [36%] vs 25 [31%]), anaemia (17 [21%] vs 20 [25%]), febrile neutropenia (nine [11%] vs five [6%]), and asthenia (eight [10%] vs seven [9%]). Two treatment-related deaths occurred in the topotecan group (both were febrile neutropenia with sepsis) and no treatment-related deaths occurred in the combination group. INTERPRETATION: Our results suggest that carboplatin plus etoposide rechallenge can be considered as a reasonable second-line chemotherapy option for patients with sensitive relapsed small-cell lung cancer. FUNDING: Amgen and the French Lung Cancer Group (Groupe Français de Pneumo-Cancérologie).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Baize N, Monnet I, Greillier L, et al. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2020. PMID: 32888454. doi:10.1016/S1470-2045(20)30461-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。